Literature DB >> 19601851

Expression and function of anti-inflammatory interleukins: the other side of the vascular response to injury.

Anthony A Cuneo1, Michael V Autieri.   

Abstract

Common to multiple vascular diseases, including atherosclerosis, interventional restenosis, and transplant vasculopathy, is a localized inflammatory reaction. Activated vascular smooth muscle cells (VSMC) respond to local inflammation and migrate from the media into the lumen of the vessel where they proliferate and synthesize cytokines which they respond to in an autocrine fashion, sustaining the progression of the lesion. The deleterious effects of pro-inflammatory cytokines, particularly immunomodulatory interleukins, on vascular pathophysiology and development of these maladaptive processes have been the subject of intense study. Although a great deal of attention has been given to the negative effects of pro-inflammatory cytokines and interleukins, relatively little has been reported on the potentially beneficial paracrine and autocrine effects of anti-inflammatory interleukins on the vascular response to injury. The vast majority of emphasis on secretion and function of anti-inflammatory mediators has been placed on leukocytes. Consequently, the role of non-immune cells, and direct effects of anti-inflammatory interleukins on vascular cells is poorly understood. We will review the molecular mechanisms whereby anti-inflammatory interleukins inhibit signal transduction and gene expression in inflammatory cells. We will review studies in which beneficial "indirect" effects of anti-inflammatory interleukins on progression of vascular disease are achieved by modulation of immune function. We will also present the limited studies in which "direct" effects of these interleukins on VSMC and endothelial cells dampen the vascular response to injury. We propose that expression of immunomodulatory cytokines by activated vasculature may represent an auto-regulatory feed back mechanism to promote resolution of the vascular response to injury.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19601851      PMCID: PMC3290808          DOI: 10.2174/157016109788340721

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  109 in total

1.  HuR as a negative posttranscriptional modulator in inflammation.

Authors:  Vicky Katsanou; Olympia Papadaki; Stavros Milatos; Perry J Blackshear; Paul Anderson; George Kollias; Dimitris L Kontoyiannis
Journal:  Mol Cell       Date:  2005-09-16       Impact factor: 17.970

2.  IL-4 and IL-13 induce protection of porcine endothelial cells from killing by human complement and from apoptosis through activation of a phosphatidylinositide 3-kinase/Akt pathway.

Authors:  John F Grehan; Brett K Levay-Young; Jeremy L Fogelson; Vanessa François-Bongarçon; Barbara A Benson; Agustin P Dalmasso
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

3.  Regulation of T cells and cytokines by the interleukin-10 (IL-10)-family cytokines IL-19, IL-20, IL-22, IL-24 and IL-26.

Authors:  Haluk B Oral; Sergei V Kotenko; Mustafa Yilmaz; Orlando Mani; Judith Zumkehr; Kurt Blaser; Cezmi A Akdis; Mübeccel Akdis
Journal:  Eur J Immunol       Date:  2006-02       Impact factor: 5.532

4.  Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10.

Authors:  Yong Liu; Dayuan Li; Jiawei Chen; Jin Xie; Sarmistha Bandyopadhyay; Dazhi Zhang; Aravind R Nemarkommula; Hongmei Liu; Jawahar L Mehta; Paul L Hermonat
Journal:  Atherosclerosis       Date:  2005-11-21       Impact factor: 5.162

5.  IL-10-induced TNF-alpha mRNA destabilization is mediated via IL-10 suppression of p38 MAP kinase activation and inhibition of HuR expression.

Authors:  Johnson Rajasingh; Evelyn Bord; Corinne Luedemann; Jun Asai; Hiromichi Hamada; Tina Thorne; Gangjian Qin; David Goukassian; Yan Zhu; Douglas W Losordo; Raj Kishore
Journal:  FASEB J       Date:  2006-08-25       Impact factor: 5.191

6.  Downregulated CD36 and oxLDL uptake and stimulated ABCA1/G1 and cholesterol efflux as anti-atherosclerotic mechanisms of interleukin-10.

Authors:  Tina Rubic; Reinhard L Lorenz
Journal:  Cardiovasc Res       Date:  2005-12-05       Impact factor: 10.787

7.  Pro-atherogenic effect of interleukin-4 in endothelial cells: modulation of oxidative stress, nitric oxide and monocyte chemoattractant protein-1 expression.

Authors:  L Walch; L Massade; M Dufilho; A Brunet; F Rendu
Journal:  Atherosclerosis       Date:  2005-10-24       Impact factor: 5.162

8.  Interleukin-10 suppresses tissue factor expression in lipopolysaccharide-stimulated macrophages via inhibition of Egr-1 and a serum response element/MEK-ERK1/2 pathway.

Authors:  Motohiro Kamimura; Christiane Viedt; Alexander Dalpke; Michael E Rosenfeld; Nigel Mackman; David M Cohen; Erwin Blessing; Michael Preusch; Christian M Weber; Jörg Kreuzer; Hugo A Katus; Florian Bea
Journal:  Circ Res       Date:  2005-07-21       Impact factor: 17.367

9.  Interleukin-10 inhibits lipopolysaccharide-induced survival and extracellular signal-regulated kinase activation in human neutrophils.

Authors:  Carol Ward; Joanna Murray; April Clugston; Ian Dransfield; Christopher Haslett; Adriano G Rossi
Journal:  Eur J Immunol       Date:  2005-09       Impact factor: 5.532

10.  Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin.

Authors:  Shannon E Dunn; Sawsan Youssef; Matthew J Goldstein; Thomas Prod'homme; Martin S Weber; Scott S Zamvil; Lawrence Steinman
Journal:  J Exp Med       Date:  2006-02-13       Impact factor: 14.307

View more
  18 in total

Review 1.  The stereotypical molecular cascade in neovascular age-related macular degeneration: the role of dynamic reciprocity.

Authors:  D Kent
Journal:  Eye (Lond)       Date:  2015-07-31       Impact factor: 3.775

2.  Regulatory T cells and Atherosclerosis.

Authors:  Jahaira Lopez Pastrana; Xiaojin Sha; Anthony Virtue; Jietang Mai; Ramon Cueto; In Ae Lee; Hong Wang; Xiao-Feng Yang
Journal:  J Clin Exp Cardiolog       Date:  2012-10-08

3.  TiO2-Based Nanotopographical Cues Attenuate the Restenotic Phenotype in Primary Human Vascular Endothelial and Smooth Muscle Cells.

Authors:  Yiqi Cao; Tejal A Desai
Journal:  ACS Biomater Sci Eng       Date:  2020-01-17

4.  On the combined effect of statins and lycopene on cytokine production by human peripheral blood cells.

Authors:  Michael Bergman; Meir Djaldetti; Hertzel Salman; Hanna Bessler
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

5.  Effect of pulsed electromagnetic field (PEMF) on infarct size and inflammation after cerebral ischemia in mice.

Authors:  Juan Carlos Pena-Philippides; Yirong Yang; Olga Bragina; Sean Hagberg; Edwin Nemoto; Tamara Roitbak
Journal:  Transl Stroke Res       Date:  2014-02-20       Impact factor: 6.829

6.  Myocardin regulates vascular smooth muscle cell inflammatory activation and disease.

Authors:  Matthew Ackers-Johnson; Amarnath Talasila; Andrew P Sage; Xiaochun Long; Ilze Bot; Nicholas W Morrell; Martin R Bennett; Joseph M Miano; Sanjay Sinha
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-01-22       Impact factor: 8.311

7.  Restenosis and therapy.

Authors:  Laszlo Denes; Laszlo Entz; Veronika Jancsik
Journal:  Int J Vasc Med       Date:  2012-02-23

8.  Monitoring bottlenose dolphin leukocyte cytokine mRNA responsiveness by qPCR.

Authors:  Amelia Ruth Hofstetter; Kirsten C Eberle; Stephanie K Venn-Watson; Eric D Jensen; Tracy J Porter; Theresa E Waters; Randy E Sacco
Journal:  PLoS One       Date:  2017-12-22       Impact factor: 3.240

9.  Anti-inflammatory effects of interleukin-19 in vascular disease.

Authors:  Ross N England; Michael V Autieri
Journal:  Int J Inflam       Date:  2012-07-15

10.  Immune response to lipoproteins in atherosclerosis.

Authors:  Sonia Samson; Lakshmi Mundkur; Vijay V Kakkar
Journal:  Cholesterol       Date:  2012-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.